This site is intended for healthcare professionals

Libtayo filed with FDA and MAA for metastatic non-small cell lung cancer with minimum 50% PD-L1.- Regeneron/Sanofi

Read time: 1 mins
Last updated:30th Oct 2020
Published:30th Oct 2020
Condition: Non Small Cell Lung Cancer
Type: drug
Register free for full access to